NCT06990529 - Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

September 18, 2028

Study Completion Date

April 13, 2029

Conditions

PIDs Linked to PI3K

Interventions

DRUG

Leniolisib

All subjects will receive leniolisib film-coated tablets (FCTs) at the same dose they were receiving when they completed the preceding study (10, 30, or 70 mg twice daily \[BID\]).

Trial Locations (1)

20892

RECRUITING

National Institute of Health, Bethesda